期刊文献+

硫酸镁联合拉贝洛尔治疗重度妊娠高血压综合征临床疗效观察 被引量:31

Clinical observation of labetalol and magnesium sulfate treatment of pregnancy-induced hypertension
下载PDF
导出
摘要 目的探讨硫酸镁联合拉贝洛尔治疗重度妊娠高血压综合征(PIH)的临床疗效。方法选择笔者所在医院2009年1月~2011年2月收治的重度PIH孕妇86例,随机分为对照组和治疗组各43例,对照组给予硫酸镁常规解痉降压,观察组则在硫酸镁基础上,应用拉贝洛尔针加入5%葡萄糖注射液中静脉点滴。结果两组患者治疗后血压控制有效率观察组明显优于对照组,差异有统计学意义(P<0.05);并发症发生率上,两组患者在宫颈裂伤、子宫过度刺激、产后出血的发生率均有显著性差异(P<0.05)。结论硫酸镁联合拉贝洛尔治疗重度PIH效果确切,能有效降低患者平均动脉血压,改善母婴结局,具有广阔的临床应用前景。 Objective To investigate the clinical efficacy of treatment of magnesium sulfate and labetalol for pregnancy induced hypertension.Methods 86 cases in January 2009 to February 2011 PIH pregnant women were treated and were randomLy divided into control and treatment group,43 cases of control group was given magnesium sulfate buck conventional spasm was observed in the magnesium sulfate group based on the application needle labetalol in 5% glucose intravenous injection.Results There were efficient control of blood pressure after treatment observation group than the control group,the difference was statistically significant(P 0.05);complication rate,the two groups in cervical laceration,uterine hyperstimulation,postpartum incidence of bleeding was significantly different(P 0.05).Conclusion Magnesium sulfate treatment of PIH combined effect of labetalol exactly can effectively reduce the mean arterial blood pressure of patients,improve maternal and child outcomes,with a broad clinical application.
作者 李丽敏
出处 《中国医药科学》 2011年第13期91-92,共2页 China Medicine And Pharmacy
关键词 拉贝洛尔 硫酸镁 妊娠高血压综合征 Labetalol Magnesium sulfate Pregnancy-induced hypertension
  • 相关文献

参考文献3

二级参考文献49

  • 1阮百根,汪洪水,尹蓓.220例社区原发性高血压患者的药学监护[J].中国全科医学,2006,9(14):1182-1183. 被引量:6
  • 2王化洲,高东明,孙德玉.镁与心血管疾病研究进展[J].中国药学杂志,1996,31(8):490-493. 被引量:15
  • 3杨艳瑞,商素洁,李晓红.妊娠期高血压疾病并发HELLP综合征12例分析[J].河北医药,2006,28(12):1183-1184. 被引量:5
  • 4刘捷临.全国妊高征及并发症的诊断处理学术研究会纪要[J].中华妇产科杂志,1993,28:26-26.
  • 5乐杰.妇产科学[M](第5版)[M].北京:人民卫生出版社,2002.244.
  • 6Rajalingam R, Parham PL. Abi-Rached. Domain shuffling has been the main mechanism forming new hominoid KIR. J Immunol,2004,172(1):356-369
  • 7Karumanchi SA, Bdolah Y. Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question.Endocrinology,2004,145(11):4835-4837
  • 8Maynard SE, Min JY, Merchan J, et al. Excess placental soluble fmslike tyrosinekinase (sFlt1)may contribute to endothelial dysfunction,hypertension, and proteinuria in preeclampsia. J Clin Invest,2003,111(5):649-658
  • 9Page NM, Woods RJ, Gardiner SM, et al. Excessive placental secretion of neurokinin B during the third trimester causes pre-eclampsia.Nature,2000,405(6788):797-800
  • 10Redman CW, Sargent IL. Pre-eclampsia, the placenta and the maternal systemic inflammatory response-a review.Placenta,2003,24 [Suppl A]:S21-27

共引文献104

同被引文献153

引证文献31

二级引证文献315

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部